Daron Street

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study

Bradley J. Monk, John A. Blessing, Daron Street et al. · Gynecologic Oncology · 2011 · 92 citations · Full text

Phase Ii Evaluation, Recurrent Uterine Leiomyosarcoma, Gynecological Surgery +5

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Robert L. Coleman, Michael W. Sill, Premal H. Thaker et al. · Gynecologic Oncology · 2015 · 70 citations · Full text

Phase Ii Evaluation, Medicine, Pharmacology +8

Interferon-γ Enhances Susceptibility of Cervical Cancer Cells to Lysis by Tumor-Specific Cytotoxic T Cells

Daron Street, Andreas M. Kaufmann, Andrew Vaughan et al. · Gynecologic Oncology · 1997 · 41 citations

Cancer Immunosurveillance, Interferon-γ Enhances Susceptibility, Cervical Cancer +10

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

Marcela G. del Carmen, John P. Micha, Laurie Small et al. · Gynecologic Oncology · 2012 · 34 citations

Gastrointestinal Oncology, Medicine, Platinum-sensitive Recurrent Ovarian +10